DEC 13, 2018 5:51 PM PST

First Non-Opioid Drug?

WRITTEN BY: Nouran Amin

Credit: NIH Common Fund

In a study published in the medical journal—PAIN, a non-opioid drug compound discovered by researchers from the National Institute of Health (NIH)—may seek to treat chronic pain without addictive consequences.

"Chronic pain is extremely challenging to treat due to a lack of effective first-line therapies," said Matt Buczynski—author of the publication in PAIN.

The drug, referred to as ML351, will work to inhibit the naturally produced enzyme 15-Lipoxygenase-1, which contributes directly to chronic pain. This type of pain is not treatable with OTC nonsteroidal anti-inflammatory drugs such as ibuprofen. These particular drugs simply treated pain by reducing inflammation—which is not enough for diminishing chronic pain.

"Our goal is to demonstrate the preclinical efficacy of ML351 for chronic pain that does not respond to nonsteroidal anti-inflammatory drugs and might otherwise be treated with opioids," explains research scientist--Ann Gregus at the School of Neuroscience, part of the College of Science at Virginia Tech.

What is the difference between chronic pain and acute pain? Well, for one acute pain occurs as a form of protection from severe self-injury i.e., touching a hot stove. For chronic pain, these signaling pathways have been chronically activated, the pain can be debilitating. To treat chronic pain in suffering patients, healthcare providers will often prescribe powerful drugs—opioids in particular like Oxycodone and other narcotics. However, with the opioid epidemic on the rise, treating chronic pain has been faced with major hurdles.

“Serious issues with long-term usage or misuse/diversion of opioids necessitate the development of alternative treatments to expand the options available to patients with chronic pain,” says Buczynski. "While opioids are highly effective medications, concerns regarding danger of their misuse have reached a fever pitch. Thus, there is critical need of novel nonopioid treatments for the effective management of chronic pain."

ML351 is believed to target a novel signaling pathway responsible for chronic pain. "ML351 may be effective for multiple types of pain, and our future studies will investigate its utility in other models of chronic pain," explains Gregus. "ML351 shows promise as a non-opioid therapeutic to treat pain states not relieved by over-the-counter medications. Future studies will determine how we can translate these findings into novel therapeutics for clinical use."

Learn more about opioid addiction on the brain, by watching this short film-based video:

Source: ScienceDaily, PAIN

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 11, 2019
Drug Discovery & Development
DEC 11, 2019
Drug To Treat Ulcerative Colitis
Biomedical researchers at the University of California—Riverside, found that the therapeutic drug ‘tofacitinib’ used in treating autoimmu...
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
IV Treatment for Traumatic Brain Injury
Scientists are now using exosomes intravenously as a method of cell-to-cell technology for treating patients with traumatic brain injury (TBI). They discov...
DEC 23, 2019
Drug Discovery & Development
DEC 23, 2019
FDA Approves New Schizophrenic Drug
The US Food and Drug Administration (FDA) has approved an atypical antipsychotic Caplyta (lumateperone; Intra-Cellular Therapies) for the treating schizoph...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
New Drug Combo Reverses Breast Cancer
Researchers from Georgetown University have found that combining a drug used for epilepsy, bipolar disorder, and migraines with a drug used to ease blood p...
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
FEB 21, 2020
Health & Medicine
FEB 21, 2020
Should You Really be Scared of the Coronavirus?
As of February 21st, the death toll for coronavirus reached 2,250, 55,707 currently infected, of which 12,066 (22%) are in a serious or critical condition....
Loading Comments...